Intratumoral heterogeneity of HER2 protein and amplification of HER2 gene in salivary duct carcinoma

被引:14
|
作者
Kondo, Yusuke [1 ]
Kikuchi, Tomoki [1 ]
Esteban, Joaquim Carreras [1 ]
Kumaki, Nobue [1 ]
Ogura, Go [1 ]
Inomoto, Chie [1 ]
Hirabayashi, Kenichi [1 ]
Kajiwara, Hiroshi [1 ]
Sakai, Akihiro [2 ]
Sugimoto, Ryousuke [2 ]
Otsuru, Mitsunobu [3 ]
Okami, Kenji [2 ]
Tsukinoki, Keiichi [4 ]
Nakamura, Naoya [1 ]
机构
[1] Tokai Univ, Sch Med, Dept Pathol, Isehara, Kanagawa 2591193, Japan
[2] Tokai Univ, Sch Med, Dept Otolaryngol, Isehara, Kanagawa 2591193, Japan
[3] Tokai Univ, Sch Med, Dept Oral & Maxillofacial Surg, Isehara, Kanagawa 2591193, Japan
[4] Kanagawa Dent Univ, Grad Sch Dent, Dept Oral Sci, Div Environm Pathol, Yokosuka, Kanagawa, Japan
关键词
heterogeneity; human epidermal growth factor receptor 2 (HER2); salivary duct carcinoma (SDC); IN-SITU HYBRIDIZATION; GROWTH-FACTOR RECEPTOR; GASTRIC-CANCER; BREAST-CANCER; PAROTID-GLAND; GASTROESOPHAGEAL JUNCTION; HER-2/NEU GENE; EXPRESSION; OVEREXPRESSION; C-ERBB-2;
D O I
10.1111/pin.12195
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Salivary duct carcinoma (SDC) is an aggressive adenocarcinoma of the salivary glands, and accounts for 1-3% of all malignant salivary gland tumors, resembling morphologically invasive ductal carcinoma (IDC) of the breast. In contrast to IDC of the breast and gastric carcinoma (GC), the study of human epidermal growth factor receptor 2 (HER2) in SDC has not progressed. Therefore, we investigated the relationship between HER2 protein expression and amplification of the HER2 gene, and compared them in terms of intratumoral heterogeneity (ITH) in 13 cases of SDC using immunohistochemistry and dual color in situ hybridization. We found seven cases with protein overexpression (53.8%) and five cases with gene amplification (38.5%) in accordance with ASCO/CAP guidelines. ITH of HER2 protein expression was seen in seven cases (53.8%). Interestingly, the ratio of the HER2 gene showed homogenous distribution with or without the presence of ITH of HER2 protein expression. SDC tends to have more ITH of HER2 protein similarly to GC, in contrast to IDC of the breast. ITH of HER2 protein in SDC has no heterogeneity of the HER2 gene amplification. The mechanism of HER2 protein expression in SDC might proceed through a more complex pathway relative to that of IDC of the breast.
引用
收藏
页码:453 / 459
页数:7
相关论文
共 50 条
  • [1] Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland
    Cornolti, Giorgio
    Ungari, Marco
    Morassi, Maria Laura
    Facchetti, Fabio
    Rossi, Elisa
    Lombardi, Davide
    Nicolai, Piero
    [J]. ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2007, 133 (10) : 1031 - 1036
  • [2] Genotypic Intratumoral Heterogeneity in Breast Carcinoma With HER2/neu Amplification
    Brunelli, Matteo
    Manfrin, Erminia
    Martignoni, Guido
    Miller, Keith
    Remo, Andrea
    Reghellin, Daniela
    Bersani, Samantha
    Gobbo, Stefano
    Eccher, Albino
    Chilosi, Marco
    Bonetti, Franco
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2009, 131 (05) : 678 - 682
  • [3] Intratumoral heterogeneity of HER2 gene amplification in occult breast cancer
    Xin Ling
    Zhang Hong
    Zhang Shuang
    Ye Jingming
    Li Ting
    Liu Yinhua
    [J]. CHINESE MEDICAL JOURNAL, 2014, 127 (20) : 3676 - 3677
  • [4] Intratumoral heterogeneity of HER2 gene amplification in occult breast cancer
    Xin Ling
    Zhang Hong
    Zhang Shuang
    Ye Jingming
    Li Ting
    Liu Yinhua
    [J]. 中华医学杂志(英文版), 2014, (20) : 3676 - 3677
  • [5] HER2 expression and gene amplification in salivary duct cancer (SDC).
    Tamborini, E
    Negri, T
    Dagrada, G
    Locati, LD
    Guzzo, M
    Licitra, L
    Bossi, P
    Rinaldi, G
    Cantù, G
    Pierotti, MA
    Pilotti, S
    [J]. CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6232S - 6232S
  • [6] HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
    Sasagu Kurozumi
    Mary Padilla
    Masafumi Kurosumi
    Hiroshi Matsumoto
    Kenichi Inoue
    Jun Horiguchi
    Izumi Takeyoshi
    Tetsunari Oyama
    Jim Ranger-Moore
    D. Craig Allred
    Eslie Dennis
    Hiroaki Nitta
    [J]. Breast Cancer Research and Treatment, 2016, 158 : 99 - 111
  • [7] HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
    Kurozumi, Sasagu
    Padilla, Mary
    Kurosumi, Masafumi
    Matsumoto, Hiroshi
    Inoue, Kenichi
    Horiguchi, Jun
    Takeyoshi, Izumi
    Oyama, Tetsunari
    Ranger-Moore, Jim
    Allred, D. Craig
    Dennis, Eslie
    Nitta, Hiroaki
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2016, 158 (01) : 99 - 111
  • [8] HER2 Gene Amplification and Protein Expression Assessment in 44 Salivary Duct Carcinomas
    Ferguson, Donna
    Boroujeni, Amir Momeni
    Zheng, Tao
    Ho, Alan
    Arcila, Maria
    Ross, Dara
    Dogan, Snjezana
    [J]. MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 1194 - 1194
  • [9] HER2 Gene Amplification and Protein Expression Assessment in 44 Salivary Duct Carcinomas
    Ferguson, Donna
    Boroujeni, Amir Momeni
    Zheng, Tao
    Ho, Alan
    Arcila, Maria
    Ross, Dara
    Dogan, Snjezana
    [J]. LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 1194 - 1194
  • [10] Intratumoral heterogeneity of HER2 status in breast carcinoma
    Oehlschlegel, C.
    Zahel, K.
    Kradolfer, D.
    Hell, M.
    Jochum, W.
    [J]. PATHOLOGE, 2010, 31 : 292 - 295